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Introduction
The transcription factor p63, encoded by the TP63 gene, 
belongs to the p53 gene family. Distinct from the leading 
member of the gene family, p53, that plays an important role 
in tumor suppression, the role of p63 in cancer is not fully 
understood. However, p63 has been shown to be a key regu-
lator of epidermal development. This has been demonstrated 
in various animal models and by p63 mutation-associated 
human diseases. For example, complete deletion of p63 in 
mice results in the absence of the epidermis and epidermal 
related appendages, as well as defects in other epithelial-
related tissues [1–3]. In humans, heterozygous mutations in 
TP63 cause several developmental disorders, and many of 
these diseases manifest skin abnormalities [4–7]. Classical 
studies showed that p63 is an important player in embryonic 
epidermal development and in epidermal keratinocyte prolif-
eration and differentiation, where it directly regulates numer-
ous target genes involved in cell proliferation, differentiation 
and adhesion [8–10]. Several recent studies demonstrated 
that p63 also plays a role in the modulation of the epige-
netic and chromatin landscape in epidermal keratinocytes 
by directly regulating chromatin factors and by engaging 
and opening chromatin regions [11–16]. Among these stud-
ies, those using unbiased genome-wide approaches convinc-
ingly established that p63 is a key regulator controlling the 
enhancer landscape. These recent findings suggest a more 
sophisticated model of the master regulatory role of p63 
and reveal additional layers of complexity in p63-orches-
trated gene regulation of epidermal development and related 
diseases.
Different p63 isoforms have been shown to play roles in 
various cells and tissues, such as the epidermis, oocytes, 
muscles and cochlea. As such, this review discusses p63 
isoforms identified so far, with a focus on isoforms that are 
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expressed in epidermal cells. Subsequently, we dedicate 
most of this review to the most studied topic in p63 biol-
ogy: the role of p63 in epidermal development and related 
diseases. Specifically, we provide an overview of p63 muta-
tion-associated developmental diseases with epidermal 
phenotypes. We discuss in-depth key molecular and cellular 
mechanisms by which p63 controls gene regulation to define 
epidermal identity, and speculate that the affected cell fate 
contributes to various disease states. Finally, we review cur-
rent efforts and future perspectives in developing therapeutic 
strategies for treating these diseases.
p63 isoforms and their expression
The transcription factor p63 was initially described as 
keratinocyte transcription factor (KET) in 1997, as it is 
homologous to p53 in rat epithelial tissues [17]. One year 
later, it was denoted as one of the p53 gene family members 
in a comprehensive cloning study [2]. In this study, six iso-
forms resulting from two alternative promoters (TA and ΔN) 
and three different splicing routes (α, β, γ) were identified 
from mouse E15 embryos and a human neuroepithelioma 
cell line [2], indicating that these isoforms were expressed 
in those cells and tissues. The TA isoform contains three 
TA-specific exons, exon 1, 2 and 3, and encodes a transacti-
vation domain (TA1) that is homologous to the transactiva-
tion domain of the p53 protein (Fig. 1). Another promoter is 
used to produce a shorter isoform denoted ΔN, and its start-
ing exon, named as exon 3′, is specific to the ΔN isoform. 
Initially, the ΔN isoform was considered transcriptionally 
inactive, functioning as a dominant negative variant towards 
the TA isoform, because it lacks the typical transactivation 
domain TA1. However, it has since been recognized that the 
N-terminal region of the ΔN isoform also possesses transac-
tivation activity, and therefore it is termed as  TAΔN (Fig. 1). 
At the C-terminus, the longest isoform is the α isoform that 
contains all 3′ exons 11–14 (Fig. 1). At the protein level, the 
α isoform contains a sterile alpha-motif (SAM) domain that 
is thought to be involved in protein–protein interactions [2] 
and a Transactivation Inhibitory Domain (TID) that inhibits 
the activity of the TA1 domain [18]. Two other isoforms, β 
that lacks the exon 13 and γ that does not have exons 11–14 
but has a γ-specific exon 10′, do not contain the SAM and 
TID domains.
In recent years, several novel isoforms have been 
reported. At the N-terminal end of the p63 protein, an alter-
native translational start site located in the 4th exon gives 
rise to a ΔΔN isoform that lacks the first 26 amino acids of 
the ΔN isoform in epidermal keratinocytes (Fig. 1). This 
isoform was identified by Rinne et al. [19]. In their study on 
AEC/RHS syndrome, stop mutations were found within the 
first 26 amino acids of p63 in several AEC/RHS patients. To 
the surprise of the authors, the TP63 transcript was detected, 
rather than being degraded completely via the nonsense-
mediated decay mechanism that is common for stop muta-
tions. This incidental observation led to the identification of 
an alternative translational start site downstream of all stop 
mutations. This alternative translational start site gives rise 
to the ΔΔN protein variant in AEC/RHS patient keratino-
cytes, and it is also present in keratinocytes of healthy con-
trols, although at a lower level than the ΔN isoform. At the 
C-terminal end, two other isoforms, δ and ε, were identified 
by bioinformatic analyses using the Alternative Splicing 
Fig. 1  Gene and protein 
structures of p63 and muta-
tions involved in developmental 
syndromes with epidermal 
phenotypes (ectodermal 
dysplasia). Two promoters 
resulting in N-terminal TA 
and ΔN isoforms are indicated 
with arrows. Exons and protein 
domains are numbered and 
color-coded as indicated. p63 
mutation-associated ectodermal 
dysplasia syndromes are marked 
in round-edge rectangles and 
the locations of their associated 
hotspot mutations are indicated 
by black lines. The main pheno-
types related to the syndromes 
are shown near the rectangles
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Prediction Data Base, ASPicDB (http://www.caspur.it/
ASPicDB/index.php) and validated by reverse transcription 
quantitative PCR (RT-qPCR) in several cell lines including 
keratinocytes, HEK293 cells and in some tissues, such as 
the muscle and the brain [20]. The δ isoform is an alter-
natively spliced variant that lacks exon 13. The ε isoform 
is generated by a premature stop codon that is located in 
exon 10. These isoforms were later validated by an RNA-
seq analysis in mouse keratinocytes [21]. In the same mouse 
keratinocyte RNA-seq study, the authors additionally iden-
tified a slightly shorter isoform that lacks four amino acids 
encoded by nucleotides located in exon 8. Furthermore, in 
a p63 isoform analysis using RNA-seq data from squamous 
cell carcinoma (SCC) cell lines and from publically avail-
able data from cells of all three germ layer origins, Sethi 
et al. confirmed all previously reported p63 isoforms in dif-
ferent cell types [22]. Isoforms identified so far all contain 
the DNA-binding domain (DBD) and the oligomerization 
domain (OD) (Fig. 1).
Expression patterns and functions of TA and ΔN isoforms 
during epidermal commitment and subsequent stratification 
have been under debate, although it is generally agreed that 
the ΔN isoform is highly expressed in basal epithelial cells. 
One report showed that the TA isoform was expressed first 
and subsequently required to initiate epidermal stratifica-
tion, but it was counter-balanced by the ΔN isoform dur-
ing stratification [23]. In contrast, another study showed the 
ΔN isoform was required for the proliferation of epidermal 
cells in the basal layer, while the TA isoform was required 
for activating genes during stratification [24]. These studies 
proposed an interesting switch of the two isoforms during 
epidermal development. However, these observations have 
not been confirmed by other studies. The majority of current 
literature agrees that the ΔN isoform is the major functional 
isoform in epithelial cells and tissues, such as oral and den-
tal tissues, corneal tissues and lung epithelial cells [1, 3, 
25–28]. This scenario is supported by phenotypes presented 
in ΔNp63-specific knockout mouse models that, similar to 
mice that lack all p63 isoforms, showed defects of the skin, 
oral epithelium, mammary glands, limb and craniofacial 
regions [27].
As recently developed genomic approaches allow detect-
ing active promoters and expressed exons, these techniques 
greatly facilitate the identification of isoform expression 
at the transcript level. Several independent analyses using 
RNA-seq, ChIP-seq of RNA polymerase II, DNA hypersen-
sitivity sites (DHS)-seq and cap analysis gene expression 
(CAGE) [14, 22, 29] showed that the ΔN promoter is the 
only active promoter and the 3′ exon is the first expressed 
exon detected in epidermal cells throughout epidermal 
stratification. Furthermore, in line with the current litera-
ture mentioned above, Sethi et al. reported that the ΔN 
isoform is the only abundantly expressed isoform in many 
epithelial cells, such as those from oral tissues and the mam-
mary gland among 40 human cell types [22]. In contrast 
to the abundant expression of the ΔN isoform in epithelial 
cells, the TA isoform is generally expressed at a low level 
in a range of non-epithelial cells. It is expressed at a low to 
moderate level in Burkitt Lymphomas (BL) cell lines and 
the lymphoblastoid cell line GM12878 [22]. Although the 
findings from novel genomic analyses [14, 22, 29] do not 
exclude the possibility that the TA isoform is expressed at 
a very low level below the detection threshold, they do cast 
doubts on the importance of the TA isoform is in epithelial 
cells, given that its expression is at least several magnitude 
lower than the ΔN isoform. Interestingly, the TA isoform 
has been shown to play roles in various organs and tissues 
other than the epidermis. TAp63 is expressed in oocytes and 
plays an important role in controlling apoptosis in response 
to DNA damage [28]. In the cochlea, the TA isoform is also 
expressed and regulates the Notch signaling pathway, which 
is required for proper cochlea development [30]. Addition-
ally, TAp63 has been found to be expressed in late-stage 
myogenesis [31] and in cardiomyocyte development [32]. 
In general, the TA isoform seems to play a role in stress- or 
condition-induced response and in senescence, aging and 
metabolism [20, 27–30]. Many of these reported functions of 
the TA isoform are consistent with phenotypes observed in 
TA-specific mouse models [33–35], and accordingly, these 
phenotypes of TA-specific mouse models are distinct from 
the strong epidermal, orofacial and limb phenotypes of the 
p63 ΔN-specific or complete knockout mouse models [1, 
3, 27].
As for p63 C-terminal isoforms, the α isoform is the pre-
dominant one in most p63-expressing cells [22], although β, 
δ and ε isoforms are also expressed at a low level [20, 22]. 
The γ isoform is reported to be expressed in muscle cells 
[20, 31], immortalized cancer cells, such as MCF7 [20] and 
squamous cell carcinoma cell lines [22]. As the α isoform is 
by far the most abundant isoform in cells detected so far, it 
has been proposed that the bulk of the p63 functional activ-
ity is driven by the α isoform [22]. Further biochemical and 
functional in vivo analyses of other isoforms will be impor-
tant for dissecting their function.
p63 mutation‑associated diseases with ectodermal 
dysplasia
Although p63 isoforms are expressed in a range of tissues 
of different germ layer origins, germline mutations of TP63 
have until now only been associated with ectodermal-related 
disorders manifested with three hallmark defects: ectoder-
mal dysplasia, limb malformation and orofacial clefting [5]. 
These diseases include Ectrodactyly, Ectodermal Dyspla-
sia, and Cleft lip/palate syndrome (EEC, OMIM 604292), 
 E. Soares, H. Zhou 
1 3
Ankyloblepharon-Ectodermal defects-Cleft lip/palate (AEC, 
OMIM 106260), Limb Mammary Syndrome (LMS, OMIM 
603543), Acro-Dermato-Ungual-Lacrimal-Tooth syndrome 
(ADULT, OMIM 103285), Rapp–Hodgkin Syndrome (RHS, 
OMIM 129400). There is good genotype–phenotype correla-
tion in p63 mutation-associated syndromes. For examples, 
p63 mutations associated with EEC syndrome are exclu-
sively found in the DNA-binding domain of the protein, and 
those associated with AEC or RHS syndrome are located 
either at the N-terminal  TAΔN domain or C-terminal TID or 
SAM domain of the ΔNp63α isoform [5] (Fig. 1).
Among these disorders, EEC syndrome is the proto-
type of p63 mutation-associated disorders, as it exhibits 
defects of all three hallmarks. About 30% of EEC patients 
have skin defects, and the skin is often thin and dry and 
sometimes resembles dermatitis. Other affected tissues 
with ectodermal origin include hair, teeth, nails, and lac-
rimal ducts (Table 1). These phenotypes are reminiscent 
of those of p63 ΔN-specific or complete knockout mouse 
models [5], although in less severe forms. More than 90% 
of EEC syndrome patients carry heterozygous mutations in 
the p63 DNA-binding domain with a few hot spots of amino 
acids residues R204, R227, R279, R280, and R304. Tran-
sient transfection assays and in vitro DNA-binding assays 
have shown that these mutations disrupt p63 binding to 
DNA and act in a dominant negative fashion [36–38]. Two 
other syndromes with p63 mutations in the DNA-binding 
domain are LMS and ADULT syndromes. Both syndromes 
have mammary gland hypoplasia (Table 1). However, LMS 
patients rarely have defects in their skin and hair pheno-
types, whereas ADULT patients have skin, nail and teeth 
defects. LMS mutations are also found in N-terminal  TAΔN 
and C-terminal SAM domains of p63. For ADULT syn-
drome, the amino acid R298 in the DNA-binding domain 
is the most significant hot spot of mutations [39]. Rather 
than the dominant negative model that is proposed for EEC 
mutations, R298 mutations implicated in ADULT syn-
drome are proposed to be gain-of-function [36]. Another 
reported ADULT syndrome mutation is N6H, located in the 
ΔN-specific domain of p63 (Fig. 1) [5].
Among all p63 mutation-associated syndromes, the 
most severe skin phenotypes are observed in AEC/RHS 
syndromes (Table 1). About 70–75% patients have severe 
skin erosions that sometimes resemble second-degree burns 
[40]. Defects of nails and teeth are also common phenotypes 
in AEC/RHS patients. In general, the ectodermal dysplasia 
phenotypes are milder in RHS, compared to AEC. Muta-
tions involved in AEC/RHS syndromes, either in the N- or 
C-terminal region of the ΔNp63α, have been shown to dis-
rupt the transactivation activity of the ΔNp63α isoform in 
a dominant fashion.
It is generally believed that dominant negative or gain-of-
function is the disease mechanism of TP63 mutations. This 
notion is supported by several lines of evidence. First, TP63 
mutations associated with human syndromes are heterozy-
gous, and mostly missense mutations [5]. In a disease case 
where the complete TP63 gene was lost in a larger genomic 
deletion region, the patient did not present any ectoderm 
dysplasia phenotype [41]. Second, studies using in vitro bio-
chemical methods, such as transient transfection, DNA-bind-
ing assays and molecular structure modeling demonstrated 
that mutant p63 has dominant negative or gain-of-function 
effect towards the wild-type p63 [36, 38, 39]. Third, het-
erozygous p63 knockout mouse models do not exhibit any 
epidermal phenotype. To model the dominant negative or 
gain-of-function effect of TP63 mutations in human disease, 
two knock-in mouse models carrying Trp63 (encoding p63 
in mice) mutations recapitulating EEC (R279H in human) 
[42] and AEC (L514F in human) [43] were reported. In the 
EEC knock-in model, one mouse allele carried a floxed neo-
mycin cassette, and is herein referred to as  Trp63R279HN. Het-
erozygous  Trp63R279HN mice exhibited phenotypes that are 
similar to those observed in EEC syndrome patients. This 
includes cleft palate, anomalies of the distal limbs, defec-
tive tooth morphogenesis, and dystrophic nails. Although 
no major skin abnormalities were detected in  Trp63R279HN 
mice, primary keratinocytes from these mice exhibit reduced 
proliferation and increased senescence. Furthermore, an 
increased level of p63 mRNA and protein was detected in 
 Trp63R279HN mice, which is consistent with observations 
reported in the epidermis of p63 EEC patients [38]. The 
Table 1  Phenotypes of skin and ectodermal-derived appendages in p63 mutation-associated syndromes
Skin Ectodermal-derived appendages
EEC syndrome Mild phenotype—dry and thin skin Hair, nails, teeth and glands defects- highly variable severity
Limb mammary syndrome (LMS) Rarely detected Nails and lacrimal ducts defects, hypohydrosis, nipple hypoplasia and 
orofacial clefting
ADULT syndrome Dry skin—milder than EEC Teeth, nail and lacrimal duct defects
AEC syndrome Severe skin erosions Eyelid fusion, teeth and hair defects and/or alopecia, lacrimal duct 
obstruction and orofacial clefting
Rapp-Hodgkin syndrome (RHS) Severe skin erosions Teeth and hair defects and/or alopecia, lacrimal duct obstruction and 
orofacial clefting
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heterozygous AEC L514F mouse model presents hypoplas-
tic and fragile skin, ectodermal dysplasia and cleft palate, 
resembling defects observed in AEC syndrome patients [5]. 
These phenotypes probably result from impaired FGF sign-
aling, as two p63 direct target genes Fgfr2 and Fgfr3 showed 
reduced expression [43].
p63‑dependent gene regulation in epidermal 
keratinocytes
Due to the striking epidermal phenotype of p63 knockout 
mouse models and of p63 mutation-associated human dis-
eases, the molecular and cellular role of p63 in epidermal 
keratinocytes has been extensively studied. It has been 
shown that p63 is important in both keratinocyte prolifera-
tion and differentiation [10, 44]. Higher p63 expression level 
is found in more proliferative cells, such as holoclones that 
represent epidermal stem cells [9], indicating that p63 is 
important for keratinocyte proliferation. Many studies have 
used siRNA knock-down approaches to investigate the role 
of p63 in proliferation and differentiation. Knock-down of 
p63 in primary keratinocytes gives rise to hypoplasia, hypo-
proliferation, cell cycle arrest [10] and abnormalities in cell 
adhesion [8]. Furthermore, downregulation of p63 prevents 
cells from differentiating and stratifying in both 2D and 3D 
keratinocyte differentiation models [10]. Although prolif-
eration and differentiation are related, p63 seems to have 
independent roles in both processes. This was supported by 
a study where p63 knock-down caused both hypoplasia and 
differentiation defects, and concomitant p53 knock-down 
can rescue only the hypoplasia deficiency but not differen-
tiation defects [10]. At the molecular level, knock-down of 
p63 induces genes that control cell cycle arrest, such as p21 
(CDKN1A) [10, 45, 46], and genes that negatively regu-
late cell proliferation, such as JunB [47]. At the same time, 
knock-down of p63 downregulates genes that can positively 
regulate cell proliferation, such as Fos and c-Jun [47], and 
genes that are important for epidermal differentiation, such 
as Perp and K14 [48, 49]. Consistently, many genes that 
are involved in cell proliferation, cell cycle control, and 
keratinocyte differentiation have been shown to be direct 
target genes of p63 (see review [50]). In addition to control-
ling cell cycle genes, p63 is shown to directly regulate genes 
involved in glycolytic metabolism in human keratinocytes, 
such as hexokinase 2 (HK2) and 6-phosphofructo-2-kinase/
fructose-2,6-bisphosphatase 3 (PFKFB3) [51, 52]. HK2 
phosphorylates glucose to produce glucose-6-phosphate, 
representing the first rate-limiting step in glucose metabo-
lism pathways [53]. PFKFB3 is a key regulator that pro-
motes glycolysis. Downregulation of p63 resulted in reduced 
expression of HK2 and PFKFB3 and concomitant decrease 
of glycolysis and cell proliferation. These data showed that 
p63 plays a role in keratinocyte metabolism, a novel mecha-
nism to maintain high proliferation in keratinocytes [54].
The identification of p63 target genes has been a major 
effort in the field, either through dedicated candidate gene 
studies or through genome-wide explorative approaches. 
These studies identify the genomic binding regions of p63 
and of p63-regulated genes most often by either knock-down 
or overexpression of p63 [47, 55], as discussed previously in 
this review. Some target genes are identified in the context 
of p63 mutation-associated diseases [56]. It should be noted 
that p63 binding in human and mouse keratinocytes shares 
only limited conservation [57]. Epidermal development-
related genes seem to be regulated by conserved p63-bound 
genomic regions, whereas divergent p63-bound regions are 
involved in metabolic pathways. The distinct regulation 
controlled by p63 in human and mouse keratinocytes prob-
ably reflects the anatomical differences between human and 
mouse skin.
As a master regulator of epidermal development, p63 
regulates transcriptional programs not only through its target 
genes but also via higher order regulation. In recent years, 
a number of studies have shown that p63 plays a role in 
epigenetic regulation in epidermal keratinocytes via several 
independent mechanisms. p63 can recruit HDAC1/2 to con-
trol the repression of cell cycle arrest genes, such as p21 and 
14-3-3σ [46]. p63 was shown to be a repressor rather than an 
activator for cell cycle arrest genes, consistent with positive 
regulation controlled by p63 in keratinocyte proliferation. 
Furthermore, several chromatin factors are direct p63 target 
genes [11–13]. Among these factors, SATB1 regulates large-
scale chromatin remodeling in specific cell types [58, 59]. 
In keratinocytes, SATB1 binds to the Epidermal Differentia-
tion Complex (EDC) locus and compresses the conforma-
tion of EDC where many epidermal terminal differentiation 
genes are located [11]. In mice, overexpression of Satb1 can 
partially rescue the phenotype of p63-deficient mouse skin 
[11]. Another p63 direct target, BRG1, is an ATP-dependent 
chromatin remodeler. In keratinocytes, BRG1 promotes relo-
cation of the EDC locus from the nuclear periphery towards 
nuclear interior, which is associated with upregulation of 
genes in the EDC locus [12]. A chromobox protein, CBX4, 
that is a component of Polycomb Repressive Complex 1 
(PRC1), is also regulated directly by p63 [13]. CBX4 seems 
to mediate the p63-dependent repression of non-epithelial 
genes, and overexpression of CBX4 can rescue p63 defi-
ciency in keratinocytes. Chromatin remodelers that are 
direct p63 targets also include LSH, which regulates DNA 
methylation and transcriptional silencing [60]. LSH seems to 
act in p63-mediated senescence. Recently, p63 was shown to 
regulate the expression of nuclear envelop-associated com-
ponents (Lamin B1, Lamin A/C, SUN1, Nesprin-3, Plectin) 
[16]. Several nuclear shape-associated genes, such as Sun1, 
Syne3 and Plec, were shown to be p63 direct targets. In the 
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epidermis of p63 complete knockout mice, these genes were 
downregulated, and skin epithelial cells displayed an altered 
nuclear shape. Consistently, keratinocyte-specific gene loci 
were relocated away from sites of active transcription toward 
the heterochromatin-enriched repressive nuclear compart-
ments in p63 depleted cells.
In addition to regulating chromatin factors and nuclear 
envelop-associated components involved in higher order 
gene regulation in keratinocytes, it has become evident 
that p63 plays a master role in regulating enhancers. It 
should be noted that many studies discussed below took 
unbiased genomic approaches rather than p63-centered 
approaches, yet they came to the conclusion that p63 is the 
most significant transcription factor that controls epider-
mal enhancers. Bao et al. showed that genomic regions of 
p63-bound enhancers detected in keratinocytes are nucle-
osome-enriched and inaccessible in cells where p63 is not 
expressed (Fig. 2a), and the cooperation of p63 and BAF is 
required for opening chromatin (Fig. 2b, c) [61]. This sug-
gests that p63 and probably its co-regulators have a pioneer 
factor-like function during epidermal development. Pioneer 
factors are a class of transcription factors that are the first 
to engage compact chromatin and to create an accessible 
chromatin and epigenetic environment for other TFs to be 
recruited to enhancers [62–64]. They bind to target DNA 
sites before the onset of transcription, and often pioneer 
factor-bound regions are open chromatin regions in cells 
where these factors are expressed and are otherwise closed 
in cells where they are not expressed. Pioneer factors have 
been shown to be important for cell identity and commit-
ment. Consistent with this notion, another study on p53 
reported that, in addition to binding to the usual active 
promoters and enhancers of p53-regulated genes, p53 can 
also bind to inaccessible regions of the chromatin in lung 
fibroblasts [65]. Interestingly, these inactive regions in lung 
fibroblasts are seemingly active in two epithelial cells, nor-
mal human epithelial keratinocytes (NHEK) and human 
mammary epithelial cells (HMEC), but are repressed in 
other cell types. As p63 and p53 share high sequence and 
structure homology in their DNA-binding domains, and 
they bind to essentially the same binding motifs on DNA, 
it has been argued that these ‘proto-enhancers’ bound 
by p53 can be active enhancers regulated by p63 or by 
both p53 and p63 in epithelial cells. Therefore, p53 and 
p63 may function as pioneer factors. In agreement, epig-
enomic profiling analyses by ChIP-seq of histone enhancer 
marks and p63 [14, 29] and by mapping of DNA (hydroxy)
methylation sites [15] during keratinocyte differentiation 
showed that epidermal enhancers are most significantly 
enriched for p63-binding motifs and that p63 binds mainly 
to enhancers. p63-bound enhancers are not always active 
in regulating nearby genes (Fig. 2b). It has been proposed 
that these p63-bound genomic loci are bookmarked by 
p63. In particular epithelial cell types or at developmental 
stages, p63 cooperates with specific transcription factors to 
activate gene expression in a cell type- and developmental 
stage-specific manner (Fig. 2c) [14, 50]. Taken together, 
these observations support an appealing model where 
p63, probably together with co-regulating transcription 
and chromatin factors, such as BAF [61], acts as a pioneer 
factor to open chromatin in epithelial cells and shapes the 
enhancer landscape.
Fig. 2  The bookmarking role 
of p63 in epithelial cells. a In 
the absence of p63, either in 
embryonic stem cells before 
epidermal commitment or in 
non-epithelial somatic cells, loci 
of p63-dependent genes remain 
closed and are occupied by 
nucleosomes. b, c In epithelial 
cells where p63 is expressed, 
p63 and co-regulators such as 
BAF can engage closed chroma-
tin and promote its opening. In 
specific (embryonic) epithelial 
cell types, some genomic loci 
are bookmarked by p63 but 
nearby genes are not activated 
by p63. These open chromatin 
sites are marked by H3K4me1 
(b). Other loci and genes are 
bookmarked and activated by 
p63. These regions are marked 
by active enhancer mark 
H3K27ac (c)
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In summary, p63 is likely to regulate gene expression in 
epidermal keratinocytes at several levels: it regulates direct 
target genes involved in keratinocyte proliferation and dif-
ferentiation; it directly regulates chromatin and epigenetic 
factors; and it might act as a pioneer factor to shape the chro-
matin and enhancer landscape, and thereby regulate global 
gene expression.
p63 is essential for proper epidermal commitment
Consistent with the recent proposed pioneer role of p63 in 
epidermal development, classical studies in mice nearly two 
decades ago showed that p63 is essential for proper epider-
mal commitment [1, 3]. Two different groups reported that 
mouse models lacking p63 show striking defects of the epi-
dermis including either partial [1] or complete [3] absence 
of stratified epithelia. During early vertebrate development, 
the surface epithelium is composed of a single layer of K8/
K18-positive ectodermal cells [66]. This single-layered 
epithelia is functionally important for cellular diffusion, 
secretion or absorption, but not directly relevant for barrier 
function [67]. As development proceeds, these ectodermal 
cells develop into keratinocytes that have high expression of 
mature epithelial markers, such as K5/K14 and can further 
develop to the epidermis that has a barrier function. This 
physiological transition is called epidermal commitment. 
During this process, proper p63 expression and function is 
essential for correct commitment by activating epidermal 
genes and repressing genes of other lineages, and therefore 
p63 has been proposed to be the ‘gatekeeper’ of the epithe-
lial lineage [68]. Studies using in vivo and in vitro models 
and p63-regulated genes are discussed here.
Recently, spatio-temporal expression of p63 during nor-
mal mouse embryonic development was analyzed [26]. 
p63 expression was detected in ectodermal cells near the 
newly formed somites and the posterior part of the E8.5 
embryo, preceding epidermal commitment. Subsequently, 
p63 expression was enriched at branchial arches and the 
limb buds, and then expanded to the whole surface of the 
embryo. The embryonic expression pattern of p63 corre-
lates remarkably well with affected structures, such as the 
epidermis, orofacial regions and limbs in p63 knockout mice 
and in p63 mutation-associated human diseases. In normal 
mice, the single-layered epithelium eventually develops into 
stratified epithelium, whereas the surface ectoderm of p63 
null mouse strains remains a monolayer of non-proliferating 
cells expressing K8/K18 [68]. Interestingly, genetic com-
plementation with ∆Np63 in p63 null mice rescues the 
development of the skin through activation of epidermal 
genes, such as the direct p63 target K14 [69], emphasiz-
ing the important role of ∆Np63 in epidermal development. 
Consistently, in vitro studies using mouse embryonic stem 
cells (mESCs) showed that p63 expression is detected before 
expression of the epidermal marker K14 [70–73]. p63 defi-
ciency in mESCs impedes progression towards the strati-
fied epithelial fate, and p63-deficient cells have abnormally 
upregulated mesodermal genes [6, 73], indicating loss of 
the epithelial cell fate. Furthermore, ectopic expression of 
ΔNp63 in mESC-derived p63-deficient ectodermal cells can 
induce epidermal commitment and lead to differentiation 
into keratinocytes [6, 70]. It has become evident that p63 
induces expression of many epidermal genes, such as K14, 
K17 and S100A11, by directly binding to these gene loci 
[68]. However, it is also important to investigate whether 
repressed expression of genes from other lineages is directly 
regulated by p63 or through p63-related higher order regula-
tion. In summary, these in vivo and in vitro studies support 
the master regulatory role of p63 in epidermal commitment.
Although the essential role of p63 in epidermal commit-
ment has been established, the gene networks and regulatory 
mechanisms of epidermal commitment that are upstream and 
downstream of p63 are not yet fully understood. A closer 
look into molecular pathways during epidermal development 
reveals the interaction of p63 and bone morphogenetic pro-
tein (BMP) signaling [74]. The ΔNp63 isoform activates 
BMP signaling through direct binding in conserved regu-
latory regions on the Smad7 promoter, thereby repressing 
its expression. p63 sustains Bmp7 expression in the epider-
mis and indirectly controls Bmp4 expression in the dermis. 
Equally important, during early embryonic development, 
BMP signaling acts as an epidermal inducer by suppress-
ing the neural fate, probably via p63-regulated gene expres-
sion [66, 75, 76]. Furthermore, p63 expression is regulated 
in a positive autoregulatory manner through a long-range 
enhancer (p63LRE) [77]. This enhancer is conserved in 
both human and mouse and is also bound by several other 
transcription factors including AP2, Cebpa, Cebpb and the 
POU domain-containing protein Pou3f1. Among them, 
Cebpa, Cebpb and Pou3f1 repress p63 expression [77]. It 
has also been reported that Cebpb binds to the p63 promoter 
to repress its expression [78]. These studies help unravel 
the p63-related regulatory network controlling epidermal 
cell fate. However, continuing efforts to comprehensively 
and systematically identify p63-dependent transcriptional 
networks are warranted.
Taken together, in vivo and in vitro studies have demon-
strated that p63 is essential for epidermal commitment. The 
molecular pathways and gene regulatory mechanisms that 
act during epidermal commitment remain to be elucidated. 
It will be particularly interesting to investigate whether p63 
functions as a pioneer factor during this process, either alone 
or most probably together with other co-regulators, and how 
p63 mutations affect this process.
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p63 in cellular reprogramming
Somatic cell transdifferentiation is a process in which tran-
sient ectopic expression of lineage master regulators can 
induce conversion into a different somatic cell fate without 
passing through a pluripotent configuration [79–81]. Given 
the master regulatory role of p63 for proper epidermal com-
mitment and maintenance, hypotheses have arisen that its 
ectopic expression in non-epithelial cell types might be suf-
ficient to convert these cells to the epidermal fate. This has 
been demonstrated in a report where the combination of 
KLF4 with ΔNp63 could induce the conversion of human 
fibroblasts to keratinocyte-like cells [82] (Fig. 3a). The 
transdifferentiated cells showed positive staining for the 
basal marker K14 and were negative for fibroblast markers, 
such as MME and COL11A1. In the same study, cancer cells 
could also be converted to keratinocytes using KLF4 and 
p63, suggesting that these two transcription factors are capa-
ble of reprogramming cells to the epidermal fate even in dif-
ferent epigenetic backgrounds. Another example is the coop-
eration between p63 and PAX6 in driving limbal stem cell 
(LSC) commitment [83] (Fig. 3b). p63 is expressed in both 
epidermal keratinocytes and LSCs, whereas PAX6 is spe-
cific for LSCs. Epidermal keratinocytes and LSCs undergo 
distinct transcriptional programs during terminal differen-
tiation, with an induction of K1/10 or K3/12 expression for 
epidermal keratinocytes or LSCs, respectively. Ouyang et al. 
showed that p63 was essential for both epidermal keratino-
cyte and LSC fates, and the combination of p63 and PAX6 
defined the LSC fate, consistent with expression patterns of 
these two genes. Interestingly, LSCs with knock-down of 
PAX6 acquired the epidermal keratinocyte property of K1/
K10 induction during terminal differentiation; in contrast, 
ectopic expression of PAX6 in epidermal keratinocytes gave 
rise to LSC-like cells. This report is in line with previous 
studies where reported mutations in either in PAX6 [84] or 
p63 [85] lead to blindness resulting from limbal stem cell 
deficiency.
Two studies have also suggested that p63 plays a role in 
cell reprogramming to a pluripotent cell state. In one study, 
the authors reported that p63 enables reprogramming to 
pluripotency in mouse embryonic fibroblasts [86]. In this 
case, p63 did not induce reprogramming per se, but was 
important for maximal reprogramming efficiency. On the 
contrary, another report showed that p63 knockout mouse 
keratinocytes acquired some pluripotent signatures [87], 
suggesting that p63 blocks reprogramming to pluripotency. 
As p63 is normally not expressed in pluripotent stem cells, 
the function of p63 in pluripotency is completely unknown. 
Whether and how p63 plays a role in cell reprogramming to 
pluripotency requires further investigation.
So far, gene regulatory programs during these cell fate 
conversions have not yet been identified. The precise role of 
p63 in gene regulation during cellular reprogramming, espe-
cially towards an epithelial fate or during a switch between 
different epithelial fates, is important for understanding its 
master regulatory function controlling epithelial cell iden-
tity. Beyond exploring the fundamental biological role of 
p63, the examples discussed in this review also hold great 
potential for developing therapeutic options, e.g. converting 
human epidermal keratinocytes to LSCs for cornea regenera-
tion or to other rare epithelial types.
Potential therapeutic approaches
Other than cosmetic surgery and correction [88], there is no 
cure for p63 mutation-associated disorders. Recent improve-
ments in modeling human diseases have opened new per-
spectives on amelioration of these diseases.
Initially designed to treat cancers, the small compound 
APR-246/PRIMA-1MET was shown to interact with the 
mutant p53 core domain and promote its folding to the wild-
type conformation [89, 90]. This compound has been tested 
in a phase I/II clinical trial in patients with either hemato-
logical malignancies or hormone-refractory prostate cancer 
[91]. Given the high degree of homology in the DNA-bind-
ing domain between p53 and p63 [92], the potential of APR-
246 for restoring mutant p63 conformation and function was 
tested in two cellular models: epidermal stratification and 
corneal commitment [73, 93]. Shen et al. reported that APR-
246 rescued differentiation defects of keratinocytes estab-
lished from EEC patients carrying p63 mutations R204W 
and R304W in the DNA-binding domain, specifically in 
terms of cell morphology and gene expression in 2D and 
Fig. 3  p63-dependent transdifferentiation. a Human fibroblasts 
can be reprogrammed into Keratinocyte-like cells through ectopic 
expression of p63 and KLF4. b Keratinocytes that have high endog-
enous p63 expression can be reprogrammed into limbal stem cells by 
ectopic PAX6 expression
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3D epidermal stratification models [93]. A set of epidermal 
differentiation markers, such as K10, TGM, CysME, LCE2, 
and Filaggrin, were efficiently induced in APR-246-treated 
p63 mutant keratinocytes, approaching similar expression 
levels as observed in wild-type p63 keratinocytes. In addi-
tion, p63 target genes, such as ADH7 and Claudin-1, which 
were downregulated in p63 mutant keratinocytes, were 
upregulated upon APR-246 treatment. Another report using 
human-induced pluripotent stem cells (hiPSCs) established 
from the same EEC patients showed corneal epithelial cells 
derived from these patient hiPSCs responded to APR-246, 
and impaired corneal epithelial differentiation was res-
cued [73]. As p63 EEC mutations likely have a dominant 
negative effect towards the wild-type protein (Fig. 4a, b), 
APR-246 can probably restore mutant p63 to the wild-type 
conformation, thereby rescuing p63 DNA-binding and tar-
get gene activation (Fig. 4c). Further in-depth cellular and 
molecular analyses, such as RNA-seq and ChIP-seq, should 
be performed to comprehensively evaluate the effect and 
underlying mechanism of APR-246 on cell differentiation. 
Ultimately, in vivo studies and clinical trials are necessary 
to explore the therapeutic potential of APR-246.
In addition to small compounds, small interfering RNAs 
(siRNA) have also been explored for their therapeutic poten-
tial in treating p63 mutation-associated diseases. Novelli 
et al. reported the identification of a panel of siRNAs spe-
cifically targeting the p63 EEC R304W mutant transcripts. 
These R304W-targeting siRNAs can rescue defects during 
corneal epithelial differentiation of hiPSCs carrying the 
R304W mutation [94]. Similarly, the siRNA approach has 
also been applied to specifically target the p63 EEC R279H 
transcripts in oral mucosa epithelial stem cells (OMESCs) 
from EEC patients. Treatment with these siRNAs restored 
the epithelial differentiation capacity of these patient cells 
[95]. The success of these siRNA approaches also confirms 
the dominant negative model of p63 EEC mutations and 
demonstrates that degrading the mutant allele alone is suf-
ficient to rescue the epithelial defects caused by these muta-
tions (Fig. 4d).
In addition to approaches discussed in this review, rapidly 
emerging technological tools, such as genome editing, have 
provided new possibilities for developing therapeutic options 
for p63 mutation-associated diseases. Further in vivo studies 
and clinical trials are necessary to validate these therapeutic 
options and eventually to treat patients.
Conclusions and future perspectives
Since the discovery of the transcription factor p63 nearly two 
decades ago, its master regulatory role in the development 
of the epidermis has been extensively studied in cellular and 
animal models and at normal and diseased states. Although 
many isoforms have been identified for the p63 protein, the 
ΔNp63α is the most abundant isoform in epidermal cells 
and is probably responsible for the bulk of the functional 
p63 activity. p63 plays its key role in epidermal commitment 
and terminal differentiation, not only by regulating its direct 
target genes, but also by shaping the chromatin state, in par-
ticular, the enhancer landscape. Recent in-depth molecular 
analyses suggest that p63 functions as one of the pioneer fac-
tors for epidermal cell identity. This model is supported by 
Fig. 4  Potential therapeutic 
approaches targeting p63 muta-
tions. a In normal epidermal 
cells, p63 can bind to promoter 
and enhancer regions in the 
genome and regulate expression 
of its target genes. b Mutations 
in the DNA-binding domain of 
p63 (EEC syndrome mutations) 
disrupt p63 DNA-binding, 
thereby deregulating its target 
genes. c Silencing the mutant 
allele of EEC syndrome muta-
tions by mutation-specific siR-
NAs allows wild-type p63 bind-
ing and activation of p63 target 
genes. d The use of the small 
molecular compound APR-246/
PRIMA-1MET1 possibly changes 
the conformation of mutant p63 
protein and restores its ability to 
bind and activate its target genes
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classical cellular and in vivo studies as well as recent trans-
differentiation studies where p63 is required for epithelial 
cell lineages. Testing this pioneer factor model during epi-
dermal commitment at the molecular level and identifying 
key regulators that cooperate with p63 are critical topics for 
future research. It is plausible that p63 mutations involved 
in human disorders may deregulate gene expression by dis-
rupting the pioneer factor function and thereby the epithelial 
epigenetic landscape, subsequently giving rise to epidermal 
phenotypes. Current and ongoing efforts to understand the 
role of p63 in normal and diseased conditions are not only 
important for the fundamental insights into gene regulation 
and epidermal development, but also for the development 
of novel therapeutic strategies to treat patients with p63 
mutation-associated and other related diseases. Although 
therapeutic development for these diseases is still at its 
infancy, encouraging results of small molecule compounds 
and siRNA approaches have opened new possibilities, and 
should be extended further to eventually benefit patients.
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